Regulatory 2019-08-22 | Phase III study of Mangoral to start in H2-2019 PDF Report Presentation Webcast
2019-08-20 | Invitation to presentation of Ascelia Pharma’s Q4 report 2018/2019 PDF Report Presentation Webcast
Regulatory 2019-06-10 | Ascelia Pharma strengthens its Mangoral franchise by filing of a patent application for next generation Mangoral product PDF Report Presentation Webcast
2019-05-20 | Ascelia Pharma to present at Avanza börsdag, 22 May 2019 PDF Report Presentation Webcast
2019-05-15 | Fully financed Phase III program for Mangoral through the IPO PDF Report Presentation Webcast
2019-05-13 | Ascelia Pharma to host teleconference for presentation of interim financial report PDF Report Presentation Webcast
Regulatory 2019-05-10 | Nomination Committee appointed for AGM 2019 in Ascelia Pharma AB PDF Report Presentation Webcast
Regulatory 2019-05-07 | Ascelia Pharma received supportive feedback from EMA on the phase 3 program for Mangoral® PDF Report Presentation Webcast
Regulatory 2019-04-30 | Change in number of shares and votes in Ascelia Pharma AB (publ) PDF Report Presentation Webcast
Regulatory 2019-04-12 | Exercise of over-allotment option, stabilisation notice and end of the stabilisation period PDF Report Presentation Webcast
Regulatory 2019-04-08 | Encouraging results from the Phase I combination study with Oncoral and oral capecitabine published in the journal Cancer Chemotherapy and Pharmacology PDF Report Presentation Webcast
Regulatory 2019-03-29 | Change in number of shares and votes in Ascelia Pharma AB (publ) PDF Report Presentation Webcast
Regulatory 2019-03-12 | Trading in Ascelia Pharma’s shares on Nasdaq Stockholm commences tomorrow PDF Report Presentation Webcast
Regulatory 2019-03-06 | Ascelia Pharma’s new share issue in connection with the IPO on Nasdaq Stockholm was significantly oversubscribed PDF Report Presentation Webcast
Regulatory 2019-02-20 | Ascelia Pharma publishes prospectus in connection with Initial Public Offering on Nasdaq Stockholm PDF Report Presentation Webcast
